VTRS

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 8

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,103

Underlying: Common Stock · 2,103 shares

Expires 2024-03-05

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F9 · derivative.exercise_date: These options vested on March 5, 2017.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 7

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,164

Underlying: Common Stock · 4,164 shares

Expires 2023-03-06

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F8 · derivative.exercise_date: These options vested on March 6, 2016.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 6

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,057

Underlying: Common Stock · 11,057 shares

Expires 2022-02-22

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F7 · derivative.exercise_date: These options vested on February 22, 2015.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 5

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 1,337

Underlying: Common Stock · 1,337 shares

Expires 2021-03-02

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F6 · derivative.exercise_date: These options vested on February 27, 2015.

SEC source: 0000899243-20-031566 · doc4.xml · derivative · entry 4

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,791

Underlying: Common Stock · 9,791 shares

Expires 2021-03-02

F3 · security: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

F4 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F5 · derivative.exercise_date: These options vested on March 2, 2014.

SEC source: 0000899243-20-031566 · doc4.xml · nonDerivative · entry 3

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By Spouse

Disclosed balance after: 508

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

SEC source: 0000899243-20-031566 · doc4.xml · nonDerivative · entry 2

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Indirect · By 401(k) Plan

Disclosed balance after: 318

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

SEC source: 0000899243-20-031566 · doc4.xml · nonDerivative · entry 1

Campbell Paul · CIK 0001657568 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,420

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

F3 · balance_after: Includes 84 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

SEC source: 0000899243-20-031564 · doc4.xml · derivative · entry 4

MARK RICHARD A · CIK 0001676105 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,440

Underlying: Common Stock · 9,440 shares

Expires not disclosed

F6 · security: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F6 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F7 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F7 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031564 · doc4.xml · derivative · entry 3

MARK RICHARD A · CIK 0001676105 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,151

Underlying: Common Stock · 6,151 shares

Expires 2030-03-02

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F5 · derivative.exercise_date: These options will vest on March 2, 2021.

SEC source: 0000899243-20-031564 · doc4.xml · derivative · entry 2

MARK RICHARD A · CIK 0001676105 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,109

Underlying: Common Stock · 6,109 shares

Expires 2029-06-21

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · derivative.exercise_date: These options vested on March 2, 2020.

SEC source: 0000899243-20-031564 · doc4.xml · nonDerivative · entry 1

MARK RICHARD A · CIK 0001676105 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,228

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

SEC source: 0000899243-20-031563 · doc4.xml · derivative · entry 5

van der Meer Mohr Pauline · CIK 0001743962 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,440

Underlying: Common Stock · 9,440 shares

Expires not disclosed

F7 · security: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F7 · price: Received in exchange for, and having substantially the same terms as, restricted stock units ("RSUs") of Mylan in connection with the Combination.

F8 · derivative.exercise_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

F8 · derivative.expiration_date: Each RSU represents the right to receive one share of common stock of Viatris. The RSUs will vest on March 2, 2021.

SEC source: 0000899243-20-031563 · doc4.xml · derivative · entry 4

van der Meer Mohr Pauline · CIK 0001743962 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,151

Underlying: Common Stock · 6,151 shares

Expires 2030-03-02

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F6 · derivative.exercise_date: These options will vest on March 2, 2021.

SEC source: 0000899243-20-031563 · doc4.xml · derivative · entry 3

van der Meer Mohr Pauline · CIK 0001743962 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,352

Underlying: Common Stock · 4,352 shares

Expires 2029-03-01

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F5 · derivative.exercise_date: These options vested on March 2, 2020.

SEC source: 0000899243-20-031563 · doc4.xml · derivative · entry 2

van der Meer Mohr Pauline · CIK 0001743962 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,446

Underlying: Common Stock · 3,446 shares

Expires 2028-06-29

F3 · security: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F3 · price: Received in exchange for, and having substantially the same terms as, stock options to acquire Mylan ordinary shares in connection with the Combination.

F4 · derivative.exercise_date: These options vested on March 2, 2019.

SEC source: 0000899243-20-031563 · doc4.xml · nonDerivative · entry 1

van der Meer Mohr Pauline · CIK 0001743962 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,265

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

SEC source: 0000899243-22-031922 · doc4a.xml · nonDerivative · entry 1

KILTS JAMES M · CIK 0001025094 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,044

F1 · security: On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax).

F2 · price: Represents shares of Viatris common stock acquired in connection with the Combination on a one-for-one basis in exchange for ordinary shares of Mylan. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share.

F3 · balance_after: Includes 280 shares of common stock acquired in the distribution on November 16, 2020 by Pfizer to its stockholders of all of the issued and outstanding shares of Upjohn common stock held by Pfizer by way of pro rata dividend.

SEC source: 0000899243-20-031144 · doc4.xml · nonDerivative · entry 2

PFIZER INC · CIK 0000078003 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · kind: On November 16, 2020, the reporting person disposed of all its shares of common stock of the Issuer in connection with the spin-off of the Issuer from the reporting person.

SEC source: 0000899243-20-031144 · doc4.xml · nonDerivative · entry 1

PFIZER INC · CIK 0000078003 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 689,874,047

F1 · kind: On November 13, 2020, the reporting person acquired 689,873,947 shares of common stock of the Issuer as partial consideration for the contribution by the reporting person of certain assets and liabilities related to the reporting person's global, primarily off-patent branded and generic established medicines business to the Issuer.